Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression is a research paper published in Neuron (2020). On theSindex it has a DataRank of 7.9. It has been cited 616 times, with 200 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.964
From this paper's citation signal
Citation Network Contribution
6.9
From 200 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 200 citers.
National Institutes of Health
Grant: P30AG019610
National Institutes of Health
Grant: R01AG047928
National Institutes of Health
Grant: R01AG053987
National Institutes of Health
Grant: R01AG057907
National Institutes of Health
Grant: R01AG064909
National Institutes of Health
Grant: R01GM114260
National Institutes of Health
Grant: R01NS079796
National Institutes of Health
Grant: RF1AG057440
National Institutes of Health
Grant: U01AG046170
National Institutes of Health
Grant: U24NS072026
Arizona Department of Health Services
Grant: 211002
Arizona Biomedical Research Commission
Grant: 0011
Arizona Biomedical Research Commission
Grant: 05-901
Arizona Biomedical Research Commission
Grant: 1001
Arizona Biomedical Research Commission
Grant: 4001
American Lebanese Syrian Associated Charities
Grant: P30CA021765
NIA NIH HHS
Grant: P01 AG017216
NIA NIH HHS
Grant: U01 AG006786
NIA NIH HHS
Grant: P50 AG025711
NIA NIH HHS
Grant: U01 AG046139
NINDS NIH HHS
Grant: R01 NS080820
NIA NIH HHS
Grant: R01 AG018023
NIA NIH HHS
Grant: RF1 AG059319
NIA NIH HHS
Grant: P50 AG016574
NIA NIH HHS
Grant: RF1 AG064909
NIA NIH HHS
Grant: P01 AG003949
NIA NIH HHS
Grant: R01 AG032990
FWCI
44.42
Citation Percentile
1.0%
Influential Citations
21
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Integrated analysis of the aging brain transcriptome and proteome in tauopathy
Additional file 1 of Integrated analysis of the aging brain transcriptome and proteome in tauopathy
Additional file 1 of N6-methyladenosine dynamics in neurodevelopment and aging, and its potential role in Alzheimer’s disease
Additional file 1 of N6-methyladenosine dynamics in neurodevelopment and aging, and its potential role in Alzheimer’s disease
Additional file 9 of N6-methyladenosine dynamics in neurodevelopment and aging, and its potential role in Alzheimer’s disease
Additional file 9 of N6-methyladenosine dynamics in neurodevelopment and aging, and its potential role in Alzheimer’s disease
Additional file 1 of AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery
Additional file 1 of AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery
Additional file 1 of Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Additional file 1 of Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Additional file 2 of Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Additional file 2 of Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Additional file 3 of Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Additional file 3 of Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Additional file 4 of Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Additional file 4 of Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Additional file 5 of Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Additional file 5 of Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Additional file 12 of A transcriptome-wide association study of Alzheimer’s disease using prediction models of relevant tissues identifies novel candidate susceptibility genes
Additional file 12 of A transcriptome-wide association study of Alzheimer’s disease using prediction models of relevant tissues identifies novel candidate susceptibility genes